about
Terlipressin versus other vasoactive drugs for hepatorenal syndromeTransjugular intrahepatic portosystemic shunts for hepatorenal syndromeTerlipressin for hepatorenal syndromeTerlipressin for hepatorenal syndromeClinical manifestations of portal hypertensionAsymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisIntensive care management of patients with liver disease: proceedings of a single-topic conference sponsored by the Brazilian Society of HepatologyOutcomes of liver transplantation in patients with hepatorenal syndromeScoring systems for predicting mortality after liver transplantation.Management of cirrhotic ascitesPharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.Hepatorenal syndrome: aetiology, diagnosis, and treatment.The course of type 1 hepato-renal syndrome post liver transplantation.Corticomedullary differentiation on T1-Weighted MRI: comparison between cirrhotic and noncirrhotic patients.Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy.Review article: pharmacological treatment of hepatorenal syndrome.Anesthetic Considerations in Hepatectomies under Hepatic Vascular ControlHepatorenal syndrome: a dreaded complication of end-stage liver disease.Preoperative assessment of the patient with liver disease.Renal dysfunction in liver cirrhosis.The management and nursing care of cirrhotic ascites.Meta-analysis: terlipressin therapy for the hepatorenal syndrome.Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011.Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.Treatment of hepatorenal syndrome.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.Renal replacement therapy in special settings: extracorporeal support devices in liver failure.Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation.Hepatorenal syndrome in the intensive care unit.Acute liver failure in neonates, infants and children.Long-term outcome after liver transplantation.Recent advances in our understanding of hepatorenal syndrome.Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction.Is there a role for dialysis in patients with hepatorenal syndrome who are not liver transplant candidates?
P2860
Q24188350-492B15B7-9E04-4408-BF74-17FA7E932FB8Q24198269-894007BC-73D5-4BED-A52B-7C78776ED4D1Q24200336-D23B8887-FA95-4730-B58B-9CAEA5976F34Q24243962-EC85AC5A-0D3C-4643-8957-61D0FEDCC69FQ24633762-AEBF474E-1D3B-4D97-964C-DC52EDF26CA9Q26795604-72BF1C3C-6ADC-4053-B1AA-A878DD47B621Q26865028-B1D05ED0-B679-440E-93CF-6B3535A2C2EBQ28068506-7AB0181A-DB67-4D75-A13F-3CB00244E9DBQ34172324-3DF58D4D-4B73-4A29-ABC3-94E1C31509BCQ34475601-5252EB7B-2022-4050-9A10-038AF3147B51Q34601701-D70D599F-3F7E-450C-88E8-16F61FA04B0BQ34965513-E5DF2E72-5619-46C5-B31B-014FB94B4682Q35012890-3B7B16F6-0268-41B6-A785-92D77FD478E6Q35160366-94598A31-BC83-4497-A34F-25DB0F0B5639Q35745335-8621ACFB-594B-47CC-B45C-C6797CB12BF7Q35852815-07A0FA91-5D8F-4BD4-A07E-458A212AB1DDQ35873829-29C00340-8B27-4EC6-87B8-157915BA1244Q35873836-F039502F-0146-4DD2-B29B-98F3ACC2D210Q35873840-F7AE1E9D-55FF-47E3-9B1D-8FFFE08E6FA5Q36011525-4B260A3E-D725-4896-AC17-142EA1E80301Q36018527-FFC0A45F-81BF-4EB8-96EF-3C7AB5970E29Q36243486-2F746D83-075E-40AC-83C6-3306128A29C2Q36369769-24CBD467-CA9B-4900-930B-87E3F80F1BF2Q36444418-381300D1-9267-42AE-891A-9E2513760B87Q36583826-0C95471C-37E6-4091-A77B-84813B21C160Q36814530-17A023DF-58E4-4D86-A866-F0604EAAD4D5Q36940079-F66AE0F3-B8AD-430C-B7FD-9204D43F1170Q37141412-7AC14A2A-467C-4842-8604-570561496C26Q37605883-4F4FC882-0914-4FC5-8705-6861A39A66B7Q37626627-D1CA8B06-7C5E-491F-97E3-A8247D7F079BQ37634026-3B7C9A53-44EA-407F-8664-1328C1AD76E9Q37674956-A13308E8-EBB5-4B39-B2B9-DA3A271C2941Q37868691-04A089AA-4A3A-489A-8769-0A3411B264FEQ37899942-3EAF49D6-3A8D-4279-8E5C-4F7BF94E3E20Q37920945-726661E2-CBCC-4A19-B96A-2F650D26706EQ37948156-CD1334C9-D428-4800-A498-423AFB7F4E7FQ38002368-C49E8595-6985-4985-A773-96B9C29EA699Q38012022-45C93D4F-A759-4953-AF8B-C63CEE1ED6BBQ38188048-C01CB077-8F04-42FF-B5DC-4296E20EB022Q38195313-0933D954-6BF7-4D66-9684-76ECF6EEAB03
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im November 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2003
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Hepatorenal syndrome
@en
Hepatorenal syndrome
@nl
type
label
Hepatorenal syndrome
@en
Hepatorenal syndrome
@nl
prefLabel
Hepatorenal syndrome
@en
Hepatorenal syndrome
@nl
P1433
P1476
Hepatorenal syndrome
@en
P2093
Juan Rodés
Mónica Guevara
P304
P356
10.1016/S0140-6736(03)14903-3
P407
P577
2003-11-01T00:00:00Z